Tempus AI reported Q2 2026 revenue of $382.5 million, a 22% year-over-year increase, driven by 31% growth in oncology volume and 36% growth in Data Licensing & Modeling. The company achieved GAAP net income of $5.6 million and Adjusted EBITDA of $8.0 million. It raised full-year 2026 revenue guidance to $1.595–$1.605 billion and expects ~$65 million in Adjusted EBITDA. Tempus completed a $460 million offering of convertible senior notes due 2032, signed approximately $200 million in new data licenses, and received FDA approval for its xT Tumor Only assay. Additionally, the company announced an agreement to acquire Personalis for ~$1.5 billion.
